Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences to Present at Upcoming Investor Conferences
Live webcasts of these presentations can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: . A replay of these presentations will be archived and available on the site for a limited time following the event.CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December.
美國馬薩諸塞州劍橋，2024年11月26日（全球新聞通訊） -- wave life sciences有限公司（納斯達克：WVE），是一家專注於發掘RNA藥物廣泛潛力以改變盈健醫療的臨床階段生物技術公司，今日宣佈，首席執行官兼總裁Paul Bolno，醫學博士，MBA，計劃參加12月的兩場投資者會議。
7th Annual Evercore HealthCONx Conference
Date: Tuesday, December 3, 2024
Analyst-led fireside chat: 3:00 p.m. ET
第七屆evercore HealthCONx大會
日期：2024年12月3日星期二
分析師主導的爐邊聊天：東部時間下午3:00
Citi 2024 Global Healthcare Conference
Date: Wednesday, December 4, 2024
"Neuromuscular Disorders" panel: 1:00 p.m. ET
Citi 2024全球醫療會議
日期：2024年12月4日星期三
"神經肌肉疾病"會議：東部時間下午1:00
Live webcasts of these presentations can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: . A replay of these presentations will be archived and available on the site for a limited time following the event.
通過訪問Wave Life Sciences網站投資者關係部分的"投資者活動"可以訪問這些演示的直播網絡會議。事件後，這些演示的重播將被存檔，並在網站上有限時間內提供。
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington's disease, as well as a preclinical program in obesity. Driven by the calling to "Reimagine Possible", Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn.
關於Wave Life Sciences
Wave Life Sciences（納斯達克：WVE）是一家生物技術公司，專注於發掘RNA藥物的廣泛潛力，以改變盈健醫療。Wave的RNA藥物平台PRISm結合了多種應用、化學創新和對人類遺傳學的深入洞察，提供科學突破，以治療稀有和普遍疾病。其RNA靶向工具包包括編輯、剪接、RNA干擾和反義沉默，賦予Wave設計和可持續交付候選藥物的無與倫比的能力，能夠最佳解決疾病生物學。Wave多元化的開發管線包括杜氏肌營養不良症、α-1抗胰蛋白酶缺乏症和亨廷頓病的臨床項目，以及一個針對肥胖的臨床前項目。受到「重新想象可能」的召喚，Wave正在引領邁向一個人類潛能不再因疾病負擔而受阻的世界。Wave總部位於馬薩諸塞州劍橋。有關Wave的科學、管線和團隊的更多信息，請訪問並在X（前身爲Twitter）和LinkedIn上關注Wave。
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
投資者聯繫人：
凱特·勞斯
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
媒體聯繫：
艾麗西亞·蘇特
+1 617-949-4817
asuter@wavelifesci.com
譯文內容由第三人軟體翻譯。
